Drug Eluting Balloon Market to Expand at 10.4% CAGR by 2031, Driven by PAD Demand and Minimally Invasive Trends | Biotronik, Acotec Scientific, Opto Circuits, Medtronic, Boston Scientific

Drug Eluting Balloon Market is estimated to grow at a CAGR 10.4% during the forecast period 2024-2031.

The Drug Eluting Balloon Market report by DataM Intelligence provides comprehensive insights and analysis on key market trends, growth opportunities, and emerging challenges. With a commitment to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. By combining qualitative and quantitative research methodologies, the firm delivers in-depth reports that help clients navigate complex market dynamics, drive strategic growth, and seize new opportunities in an ever-evolving global landscape.

Download your exclusive sample report today: (corporate email gets priority access): https://datamintelligence.com/download-sample/drug-eluting-balloon-market?sg

Key Market Drivers:
Rising Prevalence of Cardiovascular and Peripheral Artery Diseases
An increasing global burden of cardiovascular conditions, particularly PAD, has escalated the demand for non-stent-based, drug-delivery solutions like DEBs, which reduce restenosis and avoid permanent implants.

Advantages Over Traditional Treatments
Drug-eluting balloons offer benefits such as reduced risk of late thrombosis, no need for long-term dual antiplatelet therapy, and the ability to treat small vessels and bifurcated lesions-areas where stents are less effective.

Technological Advancements
Innovations in balloon coating technologies, drug formulations (especially paclitaxel and sirolimus), and catheter design are enhancing procedural outcomes and expanding the application scope of DEBs in coronary and peripheral interventions.

Minimally Invasive Procedure Demand
A growing preference for minimally invasive and catheter-based procedures among both patients and clinicians is bolstering DEB adoption due to shorter hospital stays, faster recovery, and fewer complications.

Rising Geriatric Population
The global increase in elderly individuals who are at higher risk of vascular disorders has led to higher demand for safe and effective endovascular solutions, further boosting the DEB market.

Clinical Evidence and Regulatory Approvals
An expanding body of clinical trial data supporting DEB efficacy, coupled with approvals from regulatory bodies across multiple regions, is building confidence among physicians and accelerating commercial adoption.

Market Geographical Share:
The Drug-Eluting Balloon (DEB) market demonstrates varied growth patterns across regions, driven by healthcare infrastructure, patient demographics, and regulatory frameworks.

North America remains a leading region due to a strong presence of advanced healthcare facilities, higher adoption of minimally invasive cardiovascular treatments, and supportive reimbursement policies. The U.S. dominates the region, fueled by increasing cases of peripheral artery disease (PAD) and in-stent restenosis (ISR).

Europe holds a significant share, particularly in countries like Germany, France, and the UK. This can be attributed to early clinical adoption of DEB technology and favorable government initiatives supporting vascular interventions. Europe's strong clinical trial network also aids market penetration.

Asia-Pacific is emerging as a high-growth region, led by rising awareness of cardiovascular disorders and a rapidly aging population. Countries like China, Japan, and India are experiencing growing demand for advanced interventional cardiology solutions, supported by rising healthcare investments and expanding insurance coverage.

Make an Enquiry for purchasing this Report @ https://www.datamintelligence.com/enquiry/drug-eluting-balloon-market?sg

Strategic Players Driving the Drug Eluting Balloon Market: Medtronic, Boston Scientific Corporation, Cook Medical, B. Braun Melsungen AG, Koninklijke Philips N.V., Opto Circuits (India) Limited, Biotronik and Acotec Scientific.

M&A and Inorganic Growth:

Cordis' real‐world momentum: In May 2025, Cordis activated its SELUTION Global Coronary Registry, enrolling up to 10,000 patients worldwide to monitor outcomes for its SELUTION SLRTM Drug‐Eluting Balloon over five years. This marks a major step in gathering meaningful clinical data post‐launch.

Cordis-MedAlliance integration: Cordis had earlier acquired MedAlliance SA (2022), gaining rights to its SELUTION platform, and this acquisition continues driving promotional strategy in regions where the device is commercially available.

Product Launches & Regulatory Clearances:

iVascular (Spain): In April 2025, iVascular introduced its Luminor drug-coated balloon into the Japanese market, expanding its geographic footprint.

Boston Scientific (USA): In March 2024, received U.S. FDA approval for its AGENT Drug‐Coated Balloon, the first FDA-approved coronary DEB for treating in‐stent restenosis (ISR). Clinical results showed a 49% reduction in heart‐attack risk at the treated site, with low adverse event rates.

Research Methodology:

The global Drug Eluting Balloon Market research report employs a comprehensive dual-source approach, integrating both primary and secondary data collection methods to ensure robust market analysis. Our research framework systematically evaluates multiple industry-influencing variables, including regulatory frameworks and government policies, prevailing market conditions, competitive intensity levels, historical performance data, current market positioning, technological innovations and disruptions, emerging industry developments, cross-sector business impacts, market volatility patterns, growth prospects, potential market barriers, and strategic challenges facing industry participants.

Segment Covered in the Drug Eluting Balloon Market:

By Product Type (Coronary Drug Eluting Balloon, Peripheral Drug Eluting Balloon)

By Peripheral Drug Eluting Balloon (Paccocath, FreePac, TransPax, EnduraCoat, Others)

By End-Users (Hospitals, Cardiac Catheterization Laboratories, Ambulatory Surgery Centers, Others)

By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription?sg

Regional Analysis for Drug Eluting Balloon Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Most Frequently Asked Questions in the Drug Eluting Balloon Market Research Industry:

➠ Who leads the Drug Eluting Balloon industry and what's their competitive positioning regarding capacity, performance, and profitability?

➠ What growth opportunities and market challenges do Drug Eluting Balloon market vendors face?

➠ Which segments show the highest growth potential and market share distribution?

➠ What factors are driving or limiting Drug Eluting Balloon market growth?

➠ What are the dominant sales and distribution strategies in the Drug Eluting Balloon industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.